Why Fulgent Genetics Stock Was Crushing It on Friday

Core Insights - Fulgent Genetics experienced a significant stock price increase of over 8% following its second-quarter earnings release, contrasting with a nearly 2% decline in the S&P 500 index [1] Financial Performance - The company reported second-quarter revenue of nearly $82 million, representing a year-over-year increase of more than 15% [2] - Non-GAAP adjusted net income fell sharply by 56% to just over $2 million, equating to $0.07 per share [2] Analyst Expectations - Analysts had anticipated worse results, projecting an adjusted bottom-line loss of $0.18 per share on revenue of only $76 million [4] Strategic Progress - Fulgent attributed its better-than-expected results to diversification efforts, with CEO Ming Hsieh noting progress in growing revenue from laboratory services and advancing clinical trials for therapeutic development [4] Future Guidance - The company raised its revenue and adjusted bottom-line guidance for full-year 2025, now expecting "core" revenue of approximately $320 million and an adjusted net loss of $0.35 per share, surpassing analyst projections of a $0.55 net loss and revenue under $311 million [5]